Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
-
BUSINESS Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
-
BUSINESS Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
-
BUSINESS 60% of 56 Drug Makers Increase Hiring of New Graduates in FY2015; Eisai Resumed Hiring
April 20, 2015
-
BUSINESS Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
-
REGULATORY Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
-
REGULATORY Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
-
BUSINESS MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
-
ORGANIZATION Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
-
REGULATORY Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
-
REGULATORY JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
-
REGULATORY PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
-
BUSINESS Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
-
BUSINESS Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
-
BUSINESS Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
-
BUSINESS Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
-
ORGANIZATION JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
-
BUSINESS Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
-
ACADEMIA Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
-
BUSINESS Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…